215 related articles for article (PubMed ID: 36604954)
1. Preclinical Models of Follicular Cell-Derived Thyroid Cancer: An Overview from Cancer Cell Lines to Mouse Models.
Jeon MJ; Haugen BR
Endocrinol Metab (Seoul); 2022 Dec; 37(6):830-838. PubMed ID: 36604954
[TBL] [Abstract][Full Text] [Related]
2. An in vivo mouse model of metastatic human thyroid cancer.
Zhang L; Gaskins K; Yu Z; Xiong Y; Merino MJ; Kebebew E
Thyroid; 2014 Apr; 24(4):695-704. PubMed ID: 24262022
[TBL] [Abstract][Full Text] [Related]
3. Mouse Models to Examine Differentiated Thyroid Cancer Pathogenesis: Recent Updates.
Choi HR; Kim K
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446316
[TBL] [Abstract][Full Text] [Related]
4. Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers.
Schweppe RE; Pozdeyev N; Pike LA; Korch C; Zhou Q; Sams SB; Sharma V; Pugazhenthi U; Raeburn C; Albuja-Cruz MB; Reigan P; LaBarbera DV; Landa I; Knauf JA; Fagin JA; Haugen BR
Mol Cancer Res; 2019 May; 17(5):1036-1048. PubMed ID: 30733375
[TBL] [Abstract][Full Text] [Related]
5. AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma.
Kim CS; Vasko VV; Kato Y; Kruhlak M; Saji M; Cheng SY; Ringel MD
Endocrinology; 2005 Oct; 146(10):4456-63. PubMed ID: 16002527
[TBL] [Abstract][Full Text] [Related]
6. Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF.
Antonello ZA; Nucera C
Oncogene; 2014 Nov; 33(47):5397-404. PubMed ID: 24362526
[TBL] [Abstract][Full Text] [Related]
7. Mouse models of thyroid cancer: A 2015 update.
Kirschner LS; Qamri Z; Kari S; Ashtekar A
Mol Cell Endocrinol; 2016 Feb; 421():18-27. PubMed ID: 26123589
[TBL] [Abstract][Full Text] [Related]
8. Lessons from mouse models of thyroid cancer.
Kim CS; Zhu X
Thyroid; 2009 Dec; 19(12):1317-31. PubMed ID: 20001715
[TBL] [Abstract][Full Text] [Related]
9. Chromosomal aberrations in thyroid follicular-cell neoplasia: in the search of novel oncogenes and tumour suppressor genes.
Zitzelsberger H; Thomas G; Unger K
Mol Cell Endocrinol; 2010 May; 321(1):57-66. PubMed ID: 19961897
[TBL] [Abstract][Full Text] [Related]
10. Death from thyroid cancer of follicular cell origin.
Wu HS; Young MT; Ituarte PH; D'Avanzo A; Duh QY; Greenspan FS; Loh KC; Clark OH
J Am Coll Surg; 2000 Dec; 191(6):600-6. PubMed ID: 11129807
[TBL] [Abstract][Full Text] [Related]
11. Risk Patterns of Distant Metastases in Follicular, Papillary and Medullary Thyroid Cancer.
Machens A; Lorenz K; Weber F; Dralle H
Horm Metab Res; 2022 Jan; 54(1):7-11. PubMed ID: 34758495
[TBL] [Abstract][Full Text] [Related]
12. The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma.
Vanden Borre P; McFadden DG; Gunda V; Sadow PM; Varmeh S; Bernasconi M; Jacks T; Parangi S
Thyroid; 2014 Apr; 24(4):705-14. PubMed ID: 24295207
[TBL] [Abstract][Full Text] [Related]
13. Follicular thyroid cancers demonstrate dual activation of PKA and mTOR as modeled by thyroid-specific deletion of Prkar1a and Pten in mice.
Pringle DR; Vasko VV; Yu L; Manchanda PK; Lee AA; Zhang X; Kirschner JM; Parlow AF; Saji M; Jarjoura D; Ringel MD; La Perle KM; Kirschner LS
J Clin Endocrinol Metab; 2014 May; 99(5):E804-12. PubMed ID: 24512487
[TBL] [Abstract][Full Text] [Related]
14. Novel Anaplastic Thyroid Cancer PDXs and Cell Lines: Expanding Preclinical Models of Genetic Diversity.
Maniakas A; Henderson YC; Hei H; Peng S; Chen Y; Jiang Y; Ji S; Cardenas M; Chiu Y; Bell D; Williams MD; Hofmann MC; Scherer SE; Wheeler DA; Busaidy NL; Dadu R; Wang JR; Cabanillas ME; Zafereo M; Johnson FM; Lai SY
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4652-e4665. PubMed ID: 34147031
[TBL] [Abstract][Full Text] [Related]
15. TERTp mutation is associated with a shorter progression free survival in patients with aggressive histology subtypes of follicular-cell derived thyroid carcinoma.
Penna GC; Pestana A; Cameselle JM; Momesso D; de Andrade FA; Vidal APA; Araujo Junior ML; Melo M; Fernandes PV; Corbo R; Vaisman M; Sobrinho-Simões M; Soares P; Vaisman F
Endocrine; 2018 Sep; 61(3):489-498. PubMed ID: 29948935
[TBL] [Abstract][Full Text] [Related]
16. Mouse models of thyroid cancer: Bridging pathogenesis and novel therapeutics.
Jin Y; Liu M; Sa R; Fu H; Cheng L; Chen L
Cancer Lett; 2020 Jan; 469():35-53. PubMed ID: 31589905
[TBL] [Abstract][Full Text] [Related]
17. [Draft of the best medical treatment in patients with low-risk thyroid cancer].
Vlček P; Nováková D; Vejvalka J; Zimák J; Křenek M; Vošmiková K; Smutný S; Bavor P; Astl J; Lukáš J
Vnitr Lek; 2015 Sep; 61(9):769-77. PubMed ID: 26465275
[TBL] [Abstract][Full Text] [Related]
18. Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas.
Vitagliano D; Portella G; Troncone G; Francione A; Rossi C; Bruno A; Giorgini A; Coluzzi S; Nappi TC; Rothstein JL; Pasquinelli R; Chiappetta G; Terracciano D; Macchia V; Melillo RM; Fusco A; Santoro M
Oncogene; 2006 Aug; 25(39):5467-74. PubMed ID: 16785999
[TBL] [Abstract][Full Text] [Related]
19. Exosomal ANXA1 derived from thyroid cancer cells is associated with malignant transformation of human thyroid follicular epithelial cells by promoting cell proliferation.
Li Q; Liu W; Wang Z; Wang C; Ai Z
Int J Oncol; 2021 Dec; 59(6):. PubMed ID: 34779491
[TBL] [Abstract][Full Text] [Related]
20. Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin.
Fallahi P; Ferrari SM; Elia G; Ragusa F; Patrizio A; Paparo SR; Marone G; Galdiero MR; Guglielmi G; Foddis R; Cristaudo A; Antonelli A
Semin Cancer Biol; 2022 Feb; 79():203-216. PubMed ID: 32569821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
